Company Overview
Company Type: Private Company
Company Status: Operating Subsidiary
Website: www.fresenius-kabi.com
Number of Employees: 40,000
Year Founded: 1999
Total Amount Raised (CAD mm)†: -
Total Rounds of Funding**:-
Latest Post-Money Valuation ($ mm) -
Latest Pre-Money Valuation ($ mm) -
† This number reflects the estimated value of the total new money raised through private placement rounds.
** This value is an estimate of the total number of funding rounds this company has received.


Business Description
Fresenius Kabi AG develops, manufactures, and markets pharmaceuticals and medical devices for the therapy and care for critically and chronically ill patients worldwide. It offers lifesaving medicines and technologies for infusion, transfusion, and clinical nutrition. The company offers products for the treatment of anesthesia, blood volume substitution, critical illness, diabetes mellitus, fluid management, liver insufficiency, maldigestion, malabsorption, nutritional support, oncology, pediatrics, and renal insufficiency. Its product portfolio includes I.V. generic drugs, infusion therapies, clinical nutrition products, medical devices, and transfusion technology. Additionally, it also provides research and development services in the areas of oncology and autoimmune diseases. The company was founded in 1999 and is based in Bad Homburg, Germany with production sites in Europe, North America, Latin America, the Asia Pacific, and Africa. Fresenius Kabi AG operates as a subsidiary of Fresenius SE & Co. KGaA.


Financial Information (Currency: CAD, in mm)
Total Revenue
 8,030.5
Operating Income
-
Total Assets
-
Gross Profit
-
EBITDA
-
Total Debt
-
Net Income
-
Estimated Number of Employees
 40,000
Net Debt
-
* Hover over data point numbers for date and source.

Key Professionals
Name
Title
Henriksson, Mats Christer
Chairman of Management Board and Chief Executive Officer
Crouton, Marc
Member of Management Board
Ducker, John Robert
Member of Management Board
Hauer, Christian
Member of Management Board
Schonhofen, Michael 
Member of Management Board
Schulte-Noelle, Philipp
Member of Management Board
Steen, Gerrit 
Member of Management Board
Schneider, Ursula
Senior Vice President of Corporate Communications

Key Board Members
Name
Title
Schneider, Ulf Mark
Chairman of Supervisory Board
Jain, Rajiv Lochan
Additional Director


Primary Industry Classification
Pharmaceuticals


Primary Office Location
Else-KrOener-Strasse 1 | Bad Homburg, Hessen | 61352 | Germany
Phone: 49 61 72 686 0   Fax: 49 6172 686 2628

Parent Company
Fresenius SE & Co. KGaA (XTRA:FRE)


Company Notes
No Company Notes exist.


Strategy Notes
No Strategy Notes exist.


Current and Pending Subsidiaries / Investments
Company Name
Business Description
Geography
Primary Industry
LTM Total Rev.($mm)
LFQ Total Assets ($mm)
LFQ Total Debt ($mm)
Ivenix, Inc.
Ivenix, Inc. develops intravenous (IV) infusion system solutions. It offers an IV smart pump that eliminates air from the fluid bag and IV lines that reduce the number of air in line alarms; and infusion devices. Ivenix, Inc. was formerly known as Fluidnet Corporation and changed its name to Ivenix, Inc. in March, 2014. The company was incorporated in 2001 and is based in North Andover, Massachusetts. As of May 4, 2022 Ivenix, Inc operates as a subsidiary of Fresenius Kabi Aktiengesellschaft.

United States and Canada
Health Care Equipment
-
-
-
Mabxience Holding, S.L.
Mabxience Holding, S.L. engages in the development, manufacturing, and commercialization of biopharmaceutical medicines. The company was founded in 2009 and is based in Madrid, Spain. As of August 1, 2022, Mabxience Holding, S.L. operates as a subsidiary of Fresenius Kabi Aktiengesellschaft.

Europe
Biotechnology
-
-
-
Merck Kommanditgesellschaft auf Aktien, Biosimilars Business
Merck Kommanditgesellschaft auf Aktien, Biosimilars Business researches and develops pharmaceuticals focused on oncology and inflammatory disorders. The asset is located in Switzerland.

Europe
Life Sciences Tools and Services
-
-
-
Fresenius Kabi India Pvt.Ltd.
Fresenius Kabi India Pvt.Ltd. develops, manufactures, and market pharmaceuticals and medical devices. It provides infusion therapy products, such as basic solutions, infusion solutions for osmotic therapy, irrigation solutions/urology, infusion solutions for blood volume replacement and hemodilution therapy, I.V. anaesthetics, I.V. anti-infective drugs, medical devices, PDMS patient data management systems, volumetric infusion pumps and syringe pumps, infusion and clinical fluid management systems, I.V. anaesthesia and analgesia systems, and autotransfusion systems. The company also offers parenteral nutrition products, immune modulation products, enteral products, oral amino keto acids, medical devices, filter systems, and oncology products. It provides its products for therapeutics areas, such as blood volume substitution, infusion therapy, clinical nutrition, transfusion technology, enteral nutrition, fluid management, anesthesia, critical illness, oncology, liver insufficiency, and renal insufficiency worldwide. The company was founded in 1995 and is based in Pune, India. It has additional offices in Gurugram and Mumbai. Fresenius Kabi India Pvt.Ltd. operates as a subsidiary of Fresenius Kabi AG.

Asia / Pacific
Pharmaceuticals
110.00
-
-
Novafarma Indústria Farmacêutica Ltda.
Novafarma Indústria Farmacêutica Ltda. engages in the development and supply of medicines in the form of powders. The company offers products in various therapeutic areas, including cephalosporin, penicillin, aminoglycosides, systemic antibiotic, myocardium, and vasoconstrictor and hyper tensor, as well as antibiotic and drug association, bronchodilator, and antiemetic and antinauseant. It serves hospital market, distributors, health departments, private hospitals, public agencies, autarchies, associations, foundations, and city halls. The company was founded in 1994 and is based in Anápolis, Brazil. As of July 3, 2014, Novafarma Indústria Farmacêutica Ltda. operates as a subsidiary of Fresenius Kabi AG.

Latin America and Caribbean
Pharmaceuticals
34.00
-
-
PT. ETHICA Industri Farmasi
PT. ETHICA Industri Farmasi manufactures and markets pharmaceutical products. The company offers antibiotics and generic products; and injectable drugs in therapeutic areas, including gynecology, anesthesia, and intensive care. It offers its products through a network of distributors in Indonesia. The company was founded in 1946 and is based in Jakarta, Indonesia. As of October 1, 2013, PT. ETHICA Industri Farmasi operates as a subsidiary of Fresenius Kabi Aktiengesellschaft.

Asia / Pacific
Pharmaceuticals
-
-
-
Fenwal Holdings, Inc.
Fenwal Holdings, Inc. develops and delivers transfusion technology products for blood collection, separation, and processing. The company offers a range of products and services focused on apheresis collections, therapeutic procedures, and manual collection processes, as well as specialty and platelet safety products. It helps to ensure the availability, safety, and effectiveness of treatments that depend on blood. The company was incorporated in 2006 and is based in Lake Zurich, Illinois. As of December 12, 2012, Fenwal Holdings, Inc. operates as a subsidiary of Fresenius Kabi AG.

United States and Canada
Health Care Equipment
-
-
-


Last 5 Transactions
Announced Date
Closed Date
Transaction Type
Role
Target
Buyer/Investors
Sellers
Size($mm)
Jun-13-2022
-
Merger/Acquisition
Seller
PT. ETHICA Industri Farmasi
PT Pyridam Farma Tbk (IDX:PYFA),PT Pyfa Sehat Indonesia
Fresenius Kabi Aktiengesellschaft,Fresenius Kabi Deutschland Gmbh
11.11
Mar-31-2022
Aug-01-2022
Merger/Acquisition
Buyer
Mabxience Holding, S.L.
Fresenius Kabi Aktiengesellschaft
Insud Pharma S.L.U.,Invim Corporativo SL
549.88
Mar-31-2022
May-04-2022
Merger/Acquisition
Buyer
Ivenix, Inc.
Fresenius Kabi Aktiengesellschaft
Chp Management, Inc.,Fidelity Biosciences,Easterly, LLC,Stichting Lichfield,CICA, Inc.,6 Dimensions Capital, L.P. Seller Funds:WuXi Healthcare Ventures II, L.P.
240.00
Apr-24-2017
Sep-01-2017
Merger/Acquisition
Buyer
Merck Kommanditgesellschaft auf Aktien, Biosimilars Business
Fresenius Kabi Aktiengesellschaft
Merck KGaA (XTRA:MRK)
778.64
Dec-28-2015
Dec-28-2015
Merger/Acquisition
Seller
Fresenius Kabi AG, Oncological Production Plant
GP Pharm, S.A.
Fresenius Kabi Aktiengesellschaft
-
* denotes that the relationship is proprietary


Last 5 Key Developments
Date
Event Type
Headline
Jun-14-2023
Product-Related Announcements
Fresenius Kabi Launches Vasopressin Injection, USP Expanding U.S. Critical Care Portfolio
Jun-01-2023
Company Conference Presentations
Fresenius Kabi Aktiengesellschaft Presents at 2nd Annual Medical Device Safety And Regulations Compliance Forum, Jun-01-2023
May-04-2023
Company Conference Presentations
Fresenius Kabi Aktiengesellschaft Presents at LSX World Congress, May-04-2023 10:10 AM
Jan-25-2023
Company Conference Presentations
Fresenius Kabi Aktiengesellschaft Presents at Medical Device Software Development Summit Europe 2023, Jan-25-2023 11:45 AM
Nov-28-2022
Product-Related Announcements
CSL Vifor and Fresenius Kabi Announces China’s National Medical Products Administration Approves Ferinject

Competitors
Akorn Operating Company LLC, Allergan plc, Amneal Pharmaceuticals, Inc. (NYSE:AMRX), Amphastar Pharmaceuticals, Inc. (NasdaqGS:AMPH), Apotex Inc., Arcomed Ag, AstraZeneca PLC (LSE:AZN), Auro Medics Pharma Llc, B. Braun Medical Inc., Bausch & Lomb Incorporated, Bausch Health Companies Inc. (NYSE:BHC), Bayer Vietnam Ltd., Bedford Laboratories, Ben Tre Pharmaceutical Joint Stock Company (HOSE:DBT), Binh Dinh Pharmaceutical and Medical Equipment Joint Stock Company (HOSE:DBD), Boehringer Ingelheim GmbH, Cumberland Pharmaceuticals Inc. (NasdaqGS:CPIX), Cuu Long Pharmaceutical Joint Stock Company (HOSE:DCL), DHG Pharmaceutical Joint Stock Company (HOSE:DHG), Domesco Medical Import - Export Joint-Stock Corporation (HOSE:DMC), Eli Lilly and Company (NYSE:LLY), Endo International plc (OTCPK:ENDP.Q), Geneva Pharmaceuticals Technology Corporation, GSK plc (LSE:GSK), Hikma Labs Inc., Imexpharm Corporation (HOSE:IMP), Innopharma, Inc., IRadimed Corporation (NasdaqCM:IRMD), KLUS Pharma, Inc., Lamdong Pharmaceutical Joint Stock Company (HNX:LDP), Mekophar Chemical Pharmaceutical Joint Stock Company, Merck & Co., Inc. (NYSE:MRK), Mipm Mammendorfer Institut FÜR Physik Und Medizin Gmbh, Novartis AG (SWX:NOVN), Novartis International AG, Novo Nordisk A/S (CPSE:NOVO B), OPC Pharmaceutical Joint Stock Company (HOSE:OPC), Padagis US LLC, Perrigo Company plc (NYSE:PRGO), Pfizer Limited (NSEI:PFIZER), Pharmedic Pharmaceutical Medicinal Joint Stock Company (HNX:PMC), Pymepharco Joint Stock Company (UNQ-VNM:PME), Roche Holding AG (SWX:ROG), Sandoz Inc., SPM Corporation (HOSE:SPM), Sun Pharmaceutical Industries Limited (NSEI:SUNPHARMA), Taro Pharmaceutical Industries Ltd. (NYSE:TARO), The Medicines Company, Traphaco Joint Stock Company (HOSE:TRA), Xeris Biopharma Holdings, Inc. (NasdaqGS:XERS), Zealand Pharma A/S (CPSE:ZEAL)

M&A Advisors
Allen & Overy LLP, Amarchand & Mangaldas & Suresh A. Shroff & Co., Clifford Chance Partnerschaftsgesellschaft, Deutsche Bank Aktiengesellschaft (XTRA:DBK), Ernst & Young Advisory Services Indonesia, Freshfields Bruckhaus Deringer LLP, Hyman, Phelps & MacNamara, JPMorgan Chase & Co. (NYSE:JPM), KPMG Asesores S.L., Corporate Finance Arm, KPMG Transaction Services (Australia) Pty Limited., Latham & Watkins LLP, Linklaters Oppenhoff & Rädler, Linklaters, S.L.P., Mayer Brown LLP, Skadden, Arps, Slate, Meagher & Flom LLP, Walder Wyss Ltd.


Advisors
M&A Advisors
Allen & Overy LLP, Amarchand & Mangaldas & Suresh A. Shroff & Co., Clifford Chance Partnerschaftsgesellschaft, Deutsche Bank Aktiengesellschaft (XTRA:DBK), Ernst & Young Advisory Services Indonesia, Freshfields Bruckhaus Deringer LLP, Hyman, Phelps & MacNamara, JPMorgan Chase & Co. (NYSE:JPM), KPMG Asesores S.L., Corporate Finance Arm, KPMG Transaction Services (Australia) Pty Limited., Latham & Watkins LLP, Linklaters Oppenhoff & Rädler, Linklaters, S.L.P., Mayer Brown LLP, Skadden, Arps, Slate, Meagher & Flom LLP, Walder Wyss Ltd.
Public Offering Advisors
Ernst & Young LLP, Skadden, Arps, Slate, Meagher & Flom LLP


Last 10 Investment Research Documents
Contributor
Analyst
Date/Time
Company
Headline
Type
Pages
GlobalData

Sep 15, 2023 05:08 AM
Fresenius Kabi Aktiengesellschaft
Fresenius Kabi AG - Medical Devices Product Pipeline Summary
Reports
67
GlobalData

Sep 08, 2023 12:19 AM
Fresenius Kabi Aktiengesellschaft
Fresenius Kabi AG - Strategic SWOT Analysis Review
Reports
150
GlobalData

Aug 18, 2023 03:49 AM
Fresenius Kabi Aktiengesellschaft
Fresenius Kabi AG - Pharmaceuticals & Healthcare - Deals and Alliances Profile
Reports
81
GlobalData

Jun 28, 2023 04:14 AM
Fresenius Kabi Aktiengesellschaft
Fresenius Kabi AG - Pharmaceuticals & Healthcare - Deals and Alliances Profile
Reports
81
GlobalData

Jun 09, 2023 07:28 AM
Fresenius Kabi Aktiengesellschaft
Fresenius Kabi AG - Medical Devices Product Pipeline Summary
Reports
67
GlobalData

Jun 08, 2023 02:49 AM
Fresenius Kabi Aktiengesellschaft
Fresenius Kabi AG - Strategic SWOT Analysis Review
Reports
142
The Insight Partners
The Insight Partners Research Team
Mar 21, 2023 06:45 AM
Fresenius Kabi Aktiengesellschaft
Fresenius Kabi AG in Global Home Infusion Therapy Market to 2028
Notes
7
GlobalData

Mar 10, 2023 02:45 AM
Fresenius Kabi Aktiengesellschaft
Fresenius Kabi AG - Pharmaceuticals & Healthcare - Deals and Alliances Profile
Reports
85
GlobalData

Mar 10, 2023 12:52 AM
Fresenius Kabi Aktiengesellschaft
Fresenius Kabi AG - Medical Devices Product Pipeline Summary
Reports
72
GlobalData

Mar 06, 2023 11:00 PM
Fresenius Kabi Aktiengesellschaft
Fresenius Kabi AG - Strategic SWOT Analysis Review
Reports
154


S&P Global Ratings Credit Ratings
No S&P Global Ratings Credit Ratings data available. 


News Headlines
No News is currently available for the selected sources.


Company Coverage
This company is not on any Coverage List.

Products
3-Chamber Bags, Adenosine Injection, Agilia Connect, Amicus/AmiCORE (Future), Aurora/Aurora Xi (Future), Blood Volume Substitutes, CompoMat G5 Plus (Future), Freeflex+ Infusion Bag, Haloperidol Lactat, Idacio, Infusion Pumps, Intravenously Administered Drugs, Micafungin, MSB 11456 (Future), Nutritional Products, Pain Management Drugs, Pegfilgrastim (Future), Propofol, Voluven


Recent Major Filings

Key Filings
Filed On
Period Date
Company Name
Source
Form Type
Size
Oct-01-2018
Oct-01-2018
Fresenius Kabi Aktiengesellschaft
SEC
8-K (8.01, 9.01)
30 KB

Key Board Members Details
Name
Title
Phone
Fax
Email
Schneider, Ulf Mark
Chairman of Supervisory Board
49 61 72 686 0
49 6172 686 2628

Jain, Rajiv Lochan
Additional Director
49 61 72 686 0
49 6172 686 2628

* denotes that the relationship is proprietary

Key Executives and Professionals Details
Name
Title
Phone
Fax
Email
Henriksson, Mats Christer
Chairman of Management Board and Chief Executive Officer
49 61 72 686 0
49 6172 686 2628

Crouton, Marc
Member of Management Board
49 61 72 686 0
49 6172 686 2628
-
Ducker, John Robert
Member of Management Board
49 61 72 686 0
49 6172 686 2628

Hauer, Christian
Member of Management Board
49 61 72 686 0
49 6172 686 2628
-
Schonhofen, Michael 
Member of Management Board
49 61 72 686 0
49 6172 686 2628
-
Schulte-Noelle, Philipp
Member of Management Board
49 61 72 686 0
49 6172 686 2628
-
Steen, Gerrit 
Member of Management Board
49 61 72 686 0
49 6172 686 2628
-
Schneider, Ursula
Senior Vice President of Corporate Communications
49 61 72 686 0
49 6172 686 2628
-
* denotes that the relationship is proprietary

Historical Equity Pricing Data supplied by Interactive Data Pricing and Reference Data LLC 
S&P Credit Ratings and Research provided by 
No content (including ratings, credit-related analyses and data, valuations, model, software or other application or output therefrom) or any part thereof (Content) may be modified, reverse engineered, reproduced or distributed in any form by any means, or stored in a database or retrieval system, without the prior written permission of S&P Global Market Intelligence or its affiliates (collectively, S&P Global). The Content shall not be used for any unlawful or unauthorized purposes. S&P Global and any third-party providers, as well as their directors, officers, shareholders, employees or agents (collectively S&P Global Parties) do not guarantee the accuracy, completeness, timeliness or availability of the Content. S&P Global Parties are not responsible for any errors or omissions (negligent or otherwise), regardless of the cause, for the results obtained from the use of the Content, or for the security or maintenance of any data input by the user. The Content is provided on an "as is" basis. S&P GLOBAL PARTIES DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE, FREEDOM FROM BUGS, SOFTWARE ERRORS OR DEFECTS, THAT THE CONTENT’S FUNCTIONING WILL BE UNINTERRUPTED OR THAT THE CONTENT WILL OPERATE WITH ANY SOFTWARE OR HARDWARE CONFIGURATION. In no event shall S&P Global Parties be liable to any party for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including, without limitation, lost income or lost profits and opportunity costs or losses caused by negligence) in connection with any use of the Content even if advised of the possibility of such damages.

Credit-related and other analyses, including ratings, and statements in the Content are statements of opinion as of the date they are expressed and not statements of fact. S&P Global Market Intelligence’s opinions, analyses and rating acknowledgment decisions (described below) are not recommendations to purchase, hold, or sell any securities or to make any investment decisions, and do not address the suitability of any security. S&P Global Market Intelligence assumes no obligation to update the Content following publication in any form or format. The Content should not be relied on and is not a substitute for the skill, judgment and experience of the user, its management, employees, advisors and/or clients when making investment and other business decisions. S&P Global Market Intelligence does not act as a fiduciary or an investment advisor except where registered as such. While S&P Global Market Intelligence has obtained information from sources it believes to be reliable, S&P Global Market Intelligence does not perform an audit and undertakes no duty of due diligence or independent verification of any information it receives.

S&P Global keeps certain activities of its divisions separate from each other in order to preserve the independence and objectivity of their respective activities. As a result, certain divisions of S&P Global may have information that is not available to other S&P Global divisions. S&P Global has established policies and procedures to maintain the confidentiality of certain non-public information received in connection with each analytical process.

S&P Global Ratings does not contribute to or participate in the creation of credit scores generated by S&P Global Market Intelligence. Lowercase nomenclature is used to differentiate S&P Global Market Intelligence PD credit model scores from the credit ratings issued by S&P Global Ratings.

S&P Global may receive compensation for its ratings and certain analyses, normally from issuers or underwriters of securities or from obligors. S&P Global reserves the right to disseminate its opinions and analyses. S&P Global's public ratings and analyses are made available on its Web sites, www.standardandpoors.com (free of charge), and www.capitaliq.com (subscription), and may be distributed through other means, including via S&P Global publications and third-party redistributors. Additional information about our ratings fees is available at www.standardandpoors.com/usratingsfees.
Regulatory News Service data provided by 
